Syngene biologics facility to be operational for US, European customers from mid-year
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The company will provide comprehensive response to USFDA for the observations
Subscribe To Our Newsletter & Stay Updated